Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero.
about
In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical applicationHemophilia A: an ideal disease to correct in uteroLiver-targeted gene therapy: Approaches and challengesClinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A.Gene therapy for haemophilia.Perinatal gene transfer to the liver.Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.Augmentation of transgene-encoded protein after neonatal injection of adeno-associated virus improves hepatic copy number without immune responses.Treatment of Hemophilia A in Utero and Postnatally using Sheep as a Model for Cell and Gene DeliveryGenetic engineering for haemophilia A.Engineering Factor Viii for Hemophilia Gene Therapy.Genetic aspects and research development in haemostasis.Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.Gene therapy to the kidney using viral vectorsFetal gene therapy: recent advances and current challenges.Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral Vectors.Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy.HIV-1-derived lentiviral vectors and fetal route of administration on transgene biodistribution and expression in rhesus monkeys.Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice.Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors.Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.Adenovirus-mediated prenatal gene transfer to murine central nervous system.
P2860
Q26748949-E11AEEFF-3E93-4D39-B5F7-C93C54A51EF5Q26852638-0D3E5276-71F4-477F-AA5C-911AB2BC1608Q28085748-CA6DE2FF-643C-48D9-9A0A-9FC5262243A5Q33677278-292CEC5B-D895-48D3-B8AF-224405EA9CEAQ34530130-B088C6CC-E959-47AC-B709-099F1C2747A7Q35238390-5781D69F-4D33-4AF4-AA15-998A6966CAF2Q35848097-719D4C9B-2C20-4727-82D5-82255806C5D4Q35967470-205CA94C-220C-482D-BA89-89A0F7E79C5FQ36477364-2FBCC67E-4E3A-4EA9-BFCC-DBDB297D444BQ36600245-E5453CB1-D656-4719-B5C7-323F6D4B9547Q36737263-0D89FC89-681A-4587-B48B-8168C41BE811Q37176521-EF5A4686-86A6-4539-8ED4-F888E5A8F898Q37420500-7DA2EBFB-109D-497B-B4F7-A10472F16AFFQ37786559-EE7C64BD-46B5-4742-9D62-414E6F5BC728Q37881971-96D38650-E71A-4CAD-995A-F28FFC9D158CQ40041724-CE003DAB-C61A-4AF3-B9A9-E93DC1C13AA0Q40471736-8A52BEC6-E119-4E56-A290-C7960CDA2EDBQ40632785-3E541DD1-8B6B-42A2-86A0-8D3E66B56909Q41851585-B4B93E07-07FD-4F39-973C-63330B97456FQ44081593-0EC15883-636D-44BD-91C2-96CC91FEAA9FQ44536266-01B5ADD9-25F1-4133-B17F-993C45656959Q45738740-B68E9079-2871-4C78-A261-8D5F8285AE18Q45883127-8E65E856-534D-4CA8-B9F9-8445F57F57CDQ45886606-B7D4676E-EBE1-4BB3-8882-6BCEEED9D3C3
P2860
Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Short-term correction of facto ...... s murine factor VIII in utero.
@ast
Short-term correction of facto ...... s murine factor VIII in utero.
@en
type
label
Short-term correction of facto ...... s murine factor VIII in utero.
@ast
Short-term correction of facto ...... s murine factor VIII in utero.
@en
prefLabel
Short-term correction of facto ...... s murine factor VIII in utero.
@ast
Short-term correction of facto ...... s murine factor VIII in utero.
@en
P2093
P2860
P921
P356
P1476
Short-term correction of facto ...... s murine factor VIII in utero.
@en
P2093
G S Lipshutz
H Kazazian
K M Gaensler
L Flebbe-Rehwaldt
P2860
P304
13324-13329
P356
10.1073/PNAS.96.23.13324
P407
P577
1999-11-01T00:00:00Z